• Home
  • About Us
    • The Rhizen Journey
    • Leadership Team
    • What We Do
    • Our Network
  • Our Science
    • Oncology
    • The PI3K Journey
    • Onco Inflammation
    • Clinical Trials
    • Scientific Advisory Board
  • Our Pipeline
  • Partnering
    • Partnering Strategy
    • Our Partners
  • News and Events
    • From the CEO’s Desk
    • Latest News
    • Recent Publications
    • The Rhizen – Blog
  • Contact Us

Innovative Medicines

Developing next generation medicines
that will lead the fight against cancer & inflammation

Our Highlights

  • Tenalisib, our differentiated PI3K δ/γ inhibitor is now in Ph1/2 solid tumor trials
  • RP7214, our DHODH inhibitor, is in Covid-19 Ph2 trials, given its potential to limit RNA viral replication via host-directed mechanism
  • Phase 1/1b trial of RP12146, our 2nd gen PARP 1/2 inhibitor is in progress across solid tumors with promising early signs of differentiation

Relentless and innovative thinking that keeps our science

one step ahead, always!

Oncology

CANCER CELLS EVOLVE, SO DOES OUR SCIENCE

Inflammation

OUR INFLAMMMATION-FOCUSSED ASSETS

Pipeline

100% IP Ownership

Partnerships

Driving successful collaborations

OUR STORY

The Rhizen Journey!

Our journey to be a leading biopharmaceutical company developing differentiated products through cutting-edge science and strategic partnerships started in 2008.

Discover more
0 +
TARGETS

Novel programs targeting multiple hallmarks of cancer & inflammation

0 +
Trials

Assessing the safety and efficacy of our novel pipeline

0 +
PATENTS

Accumulated from dedicated research efforts for the last 12 years

Our Team

We Are All In To Make It Possible

Proven and seasoned senior leadership team with expertise spanning the entire discovery-development-commercialization value chain

Meet Our Team
OUR PARTNERING STRATEGY

Flexible Global and Regional Approach

Progress in-house assets through clinical POC/Phase II and out-license to global partners for registration and commercialization across major markets

In-license differentiated small molecule pre-clinical/IND stage assets in the Precision Oncology, Immuno-Oncology settings

Explore co-development opportunities with assets that complement Rhizen programs

Partner With Us
pricing Plans

The Best Solutions for Our Clients

Contact Us

    Cookie Policy

    Thank you for visiting this website.
    By clicking on “Accept”, you agree to the “Terms and Conditions” for continuing to use the website.

    img_box_30_orange

    Rhizen Pharmaceuticals AG, Grosspeteranlage 29,
    4052 Basel Switzerland.
    Ph No: +41 32 580 0175

    Rhizen Pharmaceuticals Inc
    726 US Highway 202 Ste 320 # 396
    Bridgewater, NJ 08807-2737

    img_box_13

    info@rhizen.com​

    twitter
    linkedin
    • About Us
    • Our Science
    • Our Pipeline
    • Partnering
    • Terms & Conditions
    • Data Protection & Privacy Policy
    • The Rhizen Journey
    • What We Do
    • Leadership Team
    • Key Strengths
    • News and Events

    © 2021 . All Rights Reserved.